RHYTHM PHARMACEUTICALS, INC. financial data

Symbol
RYTM on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 375% % -7.7%
Quick Ratio 19% % 15%
Debt-to-equity 300% % -52%
Return On Equity -267% % 66%
Return On Assets -45% % 40%
Operating Margin -101% % 50%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68,285,039 shares 7.3%
Common Stock, Shares, Outstanding 67,205,321 shares 7.7%
Entity Public Float $3,800,000,000 USD 58%
Common Stock, Value, Issued $67,000 USD 9.8%
Weighted Average Number of Shares Outstanding, Basic 64,984,361 shares 6.5%
Weighted Average Number of Shares Outstanding, Diluted 64,984,361 shares 6.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $189,757,000 USD 46%
Research and Development Expense $167,340,000 USD -30%
Costs and Expenses $381,773,000 USD -3.5%
Operating Income (Loss) $192,016,000 USD 28%
Nonoperating Income (Expense) $4,026,000 USD -177%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $196,042,000 USD 25%
Income Tax Expense (Benefit) $497,000 USD 44%
Net Income (Loss) Attributable to Parent $196,539,000 USD 25%
Earnings Per Share, Basic -3.11 USD/shares 28%
Earnings Per Share, Diluted -3.11 USD/shares 28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $54,301,000 USD -39%
Cash, Cash Equivalents, and Short-term Investments $388,900,000 USD 21%
Accounts Receivable, after Allowance for Credit Loss, Current $26,081,000 USD 41%
Inventory, Net $25,753,000 USD 37%
Other Assets, Current $9,967,000 USD 13%
Assets, Current $466,916,000 USD 25%
Other Long-term Investments $3,286,000 USD -55%
Property, Plant and Equipment, Net $1,104,000 USD 75%
Operating Lease, Right-of-Use Asset $3,049,000 USD -12%
Other Assets, Noncurrent $3,286,000 USD -55%
Assets $480,196,000 USD 22%
Accounts Payable, Current $13,947,000 USD 13%
Accrued Liabilities, Current $83,855,000 USD 34%
Liabilities, Current $105,942,000 USD -8.3%
Operating Lease, Liability, Noncurrent $3,342,000 USD -15%
Other Liabilities, Noncurrent $35,596,000 USD
Liabilities $210,170,000 USD -7.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax $796,000 USD -1941%
Retained Earnings (Accumulated Deficit) $1,351,877,000 USD -17%
Stockholders' Equity Attributable to Parent $139,069,000 USD 540%
Liabilities and Equity $480,196,000 USD 22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $40,351,000 USD 0.96%
Net Cash Provided by (Used in) Financing Activities $32,499,000 USD 666%
Net Cash Provided by (Used in) Investing Activities $24,812,000 USD -17%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 67,205,321 shares 7.7%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,958,000 USD
Deferred Tax Assets, Valuation Allowance $381,166,000 USD 17%
Deferred Tax Assets, Gross $382,164,000 USD 17%
Operating Lease, Liability $4,030,000 USD 180%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $202,674,000 USD 23%
Lessee, Operating Lease, Liability, to be Paid $5,909,000 USD 278%
Property, Plant and Equipment, Gross $6,353,000 USD 18%
Operating Lease, Liability, Current $650,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,103,000 USD 120%
Lessee, Operating Lease, Liability, to be Paid, Year One $456,000 USD -46%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,879,000 USD 1415%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,125,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $236,991,000 USD 42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,148,000 USD
Additional Paid in Capital $1,491,675,000 USD 27%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $998,000 USD -17%
Interest Expense $15,586,000 USD 55%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%